London, Canada

Michael Poulter

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 1 EPO patent. Top assignee: Owen-Barry Pharmaceuticals Inc.. Active years: 2018-2024.

USPTO Granted Patents = 5 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Michael Poulter: Innovator in Anticonvulsant Compounds

Introduction

Michael Poulter is a distinguished inventor based in London, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anticonvulsant compounds. With a total of 5 patents to his name, Poulter's work is focused on improving treatments for convulsant activity and epileptic seizures.

Latest Patents

Among his latest patents, Poulter has developed compounds and methods aimed at reducing the severity of convulsant activity or epileptic seizures. His research also extends to the treatment of chronic or acute pain, showcasing his commitment to addressing critical health issues through innovative solutions.

Career Highlights

Poulter's career is marked by his role at Owen-Barry Pharmaceuticals Inc., where he has been instrumental in advancing pharmaceutical research. His expertise in anticonvulsant compounds has positioned him as a key player in the industry, contributing to the development of effective treatments for patients suffering from seizures and pain.

Collaborations

Poulter collaborates with talented professionals in the field, including his coworker Tony Durst. Together, they work towards enhancing the efficacy of pharmaceutical products and improving patient outcomes.

Conclusion

Michael Poulter's innovative work in anticonvulsant compounds highlights his dedication to advancing medical science. His contributions are paving the way for better treatment options for individuals affected by seizures and chronic pain.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…